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Acute, persistent quinine-induced blindness
A case report
P. RHEEDER, W. L. SIELlNG
Summary
auinine-induced blindness arising during empirical treatment
for malaria in a young man is reported. The condition was
noteworthy because it was total and permanent, which is at
varia.nce with other published reports. The condition usually
disappears within minutes to weeks, but persistent deficits
tend to be l!I!1d and are rare. Although quinine is an essential
anti-malarial agent, physicians should be fully aware of
possible side-effects.
S Air Med J 1991; 79: 563-564.
Case report
A 22-year-old man presented to a peripheral hospital with a
2-day history of rigors, abdominal cramps, lumbar pain, nausea,
vomiting, dysuria and dizziness. He was given oral quinine
sulphate 600 mg and tetracycline 250 mg because malaria was
suspected clinically. The patient vomited and both drugs were
re-administered. He then became confused and disorientated
for time and place. Drowsiness, bitemporal headache, persistent
abdominal cramps, malaise, tinnitus and perception of yellow
spots in the visual field occurred. During the next 12 hours, 3
additional doses of quinine and tetracycline were administered.
On awakening next morning, the patient was totally blind. No
other drugs were prescribed, and the patient denied having
ingested Datura slramanium seeds (Jackson weed).
On admission to I Military Hospital, physical examination
revealed a young, seemingly healthy, adult male with a regular
pulse rate of 60/min, blood pressure of 140/98 mmHg and
oral temperature of 37°C. Peri-orbital swelling and conjunctival
injection were observed. The pupils were widely dilated and
responded poorly to light. Both retinas were pale and oedema-
tous on fundoscopy. The patient's visual acuity was severely
impaired, but he could still perceive movement. The quinine
was discontinued and pyrimethamine 75 mg plus sulphadoxine
I 500 mg (3 Fansidar tablets) was administered as a stat dose,
since the diagnosis of malaria could not be dismissed.
Fundoscopic examination at this stage revealed severe
arteriolar spasm. Nifedipine (10 mg 3 times a day) and oral
prednisone (60 mg/d) were administered. On the second
hospital day the visual acuity appeared to be 6 and 7,5 in the
right and left eyes, respectively. Poor accommodation and
light reflexes were present and the pupillary diameter had
decreased. Gonioscopy revealed pale retinas, severe arteriolar
spasm and areas of haemorrhage.
The serum urea, creatinine and electrolyte values were
normal while a full blood count was notable only for a white
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cell count of 15,6 X 109/rnl; liver function tests and urinalysis
were within normal limits. Two sets of slides, taken on different
occasions, for testing for malaria, and repeated blood culture
and viral serological tests (including for Rift Valley fever) were
all non-contributory.
Visual evoked potential (VEP) tests and electroretinography
(ERG) were performed on three occasions at approximately
monthly intervals. The first ERG was performed 9 days after
admission and was consistent with retinal (particularly cone)
and optic nerve dysfunction secondary to macular damage.
The second ERG showed progression of rod and cone deterio-
ration, while the third ERG remained unchanged from the
second.
Fluorescein angiography was performed 20 days after admis-
sion and showed slight disc illumination and persistent arteriolar
spasm. .
One week after admission to I Military Hospital, nimodipine
(a centrally acting calcium antagonist that dilates cerebral
vessels; not registered for use in this country at the time) I
mg/h was infused for 2 hours, followed by 2 mg/h for 40
hours. Oral nimodipine 60 mg 4-hourly was administered for a
further 72 hours. At this stage arteriolar vasospasm had
decreased, but no objective evidence of visual improvement
was demonstrable. Severe, virtually total, visual impairment of
vision has persisted.
Discussion
This' case demonstrated many of the features of qumme-
associated blindness, but differed from other reported cases of
ocular quinine toxicity in that severe, persistent total bilateral
blindness is considered to be extremely rare. 1
Systemic toxicity occurs in approximately I% of patients to
whom quinine is given. Ocular quinine toxicity is a well-
known problem, but is not dose-related. It is, however, more
common where doses in excess of 4 g have been administered,2
but has occurred with as little as 0,13 g.3 The fatal oral dose
for adults is somewhere between 3 g and 8 g.2,3 Toxicity
usually occurs when plasma concentrations exceed 5 - 8 mg/l'
and manifests as skin, visual, inner ear, central nervous system
and gastro-intestinal disturbances.5 The skin disturbances
consist of flushing and diaphoresis. Cases of mild-to-moderate
toxicity are characterised by epigastric pain, nausea, vomiting,
clouded vision, tinnitus, weakness, drowsiness, confusion, seiz-
ures, and occasionally blindness.6 In severe cases, a de?, coma
and respiratory and circulatory arrest may occur.2,5, Renal
failure and haemolysis (with anaemia) may also occur. Death is
usually due to depressed myocardial contraetility and cardiac
dysrhythmia.
Ophthalmic quinine toxicity consists of disturbed colour
perception, photophobia, diplopia, night blindness, scotomata,
mydriasis with poorly reactive pupils, iris atrophy, total blind-
ness and clouded or flickerin~ vision. I,6 Total blindness may
be delayed by several hours. I, Amblyopia is often first noted
the morning after the ingestion of quinine6 and usually lasts
for minutes to weeks, but virtually total recovery usually
occurs. Pupillary dilation (often with absent light reflexes) is
proportional to the degree of visual impairment. Severe to
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total impairment of light perception,3 hippus3 and loss of
accommodation6 may occur. Fundoscopic findings may vary
from normal3 to those compatible with pronounced retinal
artery constriction and optic disc and retinal oedema. I,5.7 Optic
atrophy and vasospasm may be demonstrable only days to
weeks later. 3,6 Brownish, macular specks may be present but
usually disappear.8 In a study of 165 patients with acute
ophthalmic quinine toxicity, plasma quinine levels were usually
higher than IS mg/l during and 10 mg/l 10 hours after
ingestion1but did not accurately predict retinal toxicity.
ERG studies at the onset of amblyopia are normal according
to some authors9 and abnormal according to others. J,1 The
paucity of ERG changes in some studies is probably due to the
late stage at which studies were performed, since the ERG
tends to return to normal as vision improves. Electro-oculo-
graphic (EOG) changes tend to parallel the decline of visual
acuity9 and suggest associated retinal pigment epithelium
involvement.9 VEP studies6 demonstrate bilateral wave-form
and linency abnormalities suggesting nerve fibre layer and
optic nerve conduction abnormalities.
Serial visual field examinations demonstrate progressive,
central, concentric return of vision - occasionally with persis-
tent tunnel vision or central scotomata. 1,5 Of 165 reported
patients with acute quinine poisoning, 19 had persistent visual
defects of which 11 were peripheral field defects, 5 central
scotomata, I defecti'le colour vision and 2 monocular blind-
ness. 1
The pathogenesis of the amblyopia is unknown, but may be
due to ischaemic neuroretinal damage secondary to retinal
vasospasm,4 as is supponed by the initially normal ERG.
Alternatively direct retinal and neural quinine toxicity may
occur/,4,8 as is suggested by the initially normal fundus in
patients with early ERG abnormalities. EOG and VEP studies
(in both patients and experimental animals) have demonstrated
retinal ganglion, nerve fibre and rod and cone atrophy. The
relative imponance of these mechanisms is uncertain.
Discontinuation of quinine therapy when amblyopia occurs
is imperative.8 Various therapies have been advocated. Many
cases of quinine-induced amblyopia resolve spontaneously ren-
dering evaluation of therapeutic options impossible. Thera-
peutic modalities that have been suggested include stellate
ganglion blockade,lo intravenous administration of ACTH, use
of vasodilators/ and enhancement of quinine elimination.
Quinine elimination is putatively increased by forced acid
diuresis,11 haemodialysis, peritoneal dialysis and plasma
exchange.2 Charcoal haemoperfusion1 decreases serum levels
but does not signilicantly decrease total body quinine after
tissue distribution has been completed.5 Nevertheless dramatic,
albeit transient, clinical improvement has occurred in haemo-
perfused patients. However, symptoms may return within
hours due to quinine redistribution and release.1 Haemo-
perfusion may be repeated until the patient is stable and is of
potential use early in the course of events while high serum
levels are present/ since there is a correlation between high
serum levels and quinine-induced blindness. I Since no evidence
of significant influence by any of these options has been
demonstrated, it may well be true that only supponive therapy
may be necessary. I
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